TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis Among Very Low Birth Weight Infants With Formula-feeding
Brief Summary: The purpose of this study is to investigate the efficacy and its mechanisms of oral mixture probiotics in preventing necrotizing enterocolitis among the preterm very low birth weight infants.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VSL#3 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VSL#3; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo
C: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
D: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis Among Very Low Birth Weight Infants With Formula-feeding
Brief Summary: The purpose of this study is to investigate the efficacy and its mechanisms of oral mixture probiotics in preventing necrotizing enterocolitis among the preterm very low birth weight infants.


Options:
A: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
C: Arm Label: Main Study; Type: N/A; Interventions: N/A | Arm Label: Gestational Diabetes Mellitus Cohort; Type: N/A; Interventions: N/A | Arm Label: Fresh Milk Cohort; Type: N/A; Interventions: N/A | Arm Label: RNA Milk Fat Cohort; Type: N/A; Interventions: N/A | Arm Label: Skin Study; Type: N/A; Interventions: N/A | Arm Label: BMMI Project; Type: N/A; Interventions: N/A
D: Arm Label: Experimental Formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: HMO supplement | Arm Label: Control Formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo comparator | Intervention Type: DIETARY_SUPPLEMENT; Name: HMO supplement; Assigned to Arm(s): Experimental Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo comparator; Assigned to Arm(s): Control Formula

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis Among Very Low Birth Weight Infants With Formula-feeding
Brief Summary: The purpose of this study is to investigate the efficacy and its mechanisms of oral mixture probiotics in preventing necrotizing enterocolitis among the preterm very low birth weight infants.


Options:
A: Arm Label: Progressive Feeding without MEF; Type: EXPERIMENTAL; Interventions: Other: Progressive Feeding without MEF | Arm Label: Progressive Feeding with MEF; Type: ACTIVE_COMPARATOR; Interventions: Other: Progressive Feeding with MEF | Intervention Type: OTHER; Name: Progressive Feeding without MEF; Assigned to Arm(s): Progressive Feeding without MEF | Intervention Type: OTHER; Name: Progressive Feeding with MEF; Assigned to Arm(s): Progressive Feeding with MEF
B: Arm Label: group 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: nutrition | Arm Label: group 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: nutrition; Assigned to Arm(s): group 1, group 2
C: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
D: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adaptive Computerized COPD Exacerbation Self-management Support (ACCESS): A Randomized Controlled Trial
Brief Summary: Aim is to test the effect of ACCESS ("Adaptive Computerized COPD Exacerbation Self-management Support"), a software application designed to support patients with COPD in self-management of exacerbations.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Tele rehab | Intervention Type: BEHAVIORAL; Name: Tele rehab; Assigned to Arm(s): Intervention group
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telerehabilitation | Intervention Type: BEHAVIORAL; Name: Telerehabilitation; Assigned to Arm(s): Intervention
C: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: telemedicine program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: telemedicine program; Assigned to Arm(s): Telemedicine
D: Arm Label: ACCESS; Type: EXPERIMENTAL; Interventions: Device: ACCESS | Arm Label: paper plan; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ACCESS; Assigned to Arm(s): ACCESS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation as Part of a Population-Based Health IT System: A Randomized Control Trial
Brief Summary: Patient navigation (PN) has been shown to improve rates of cancer screening in vulnerable populations. Most cancer PN programs are located in community health centers and focus on a single cancer. The investigators will evaluate the impact of PN program on breast, cervical, and/or colorectal cancer screening in vulnerable patients receiving care in a large, academic, primary care network using a population-based IT system.


Options:
A: Arm Label: Physical Activity Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Intervention | Arm Label: Wellness Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Wellness Control | Intervention Type: BEHAVIORAL; Name: Physical Activity Intervention; Assigned to Arm(s): Physical Activity Intervention | Intervention Type: BEHAVIORAL; Name: Wellness Control; Assigned to Arm(s): Wellness Control
B: Arm Label: Calorie-counting; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Calorie-counting | Arm Label: MyPlate; Type: EXPERIMENTAL; Interventions: Behavioral: MyPlate | Intervention Type: BEHAVIORAL; Name: Calorie-counting; Assigned to Arm(s): Calorie-counting | Intervention Type: BEHAVIORAL; Name: MyPlate; Assigned to Arm(s): MyPlate
C: Arm Label: Patient Navigation Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Navigation | Arm Label: Standard of Care - No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patient Navigation; Assigned to Arm(s): Patient Navigation Intervention
D: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Short Educational Video on OSA Patient Satisfaction, Knowledge and Outcomes
Brief Summary: The purpose of this study is to determine how satisfied patients are when undergoing an overnight polysomnogram (sleep study), what their knowledge about sleep apnea is, and what factors affect obstructive sleep apnea (OSA) treatment use.


Options:
A: Intervention Type: DEVICE; Name: CPAP (Continuous Positive Airway Pressure); Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: continuous positive airway pressure; Assigned to Arm(s): N/A
C: Arm Label: Enhanced education and Enhanced follow up; Type: EXPERIMENTAL; Interventions: Other: Enhanced education, Other: Usual follow up | Arm Label: Usual education and Usual follow up; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual education, Other: Enhanced follow up | Arm Label: Enhanced education and Usual follow up; Type: EXPERIMENTAL; Interventions: Other: Enhanced education, Other: Enhanced follow up | Arm Label: Usual education with Enhanced follow up; Type: EXPERIMENTAL; Interventions: Other: Usual education, Other: Usual follow up | Intervention Type: OTHER; Name: Enhanced education; Assigned to Arm(s): Enhanced education and Enhanced follow up, Enhanced education and Usual follow up | Intervention Type: OTHER; Name: Usual education; Assigned to Arm(s): Usual education and Usual follow up, Usual education with Enhanced follow up | Intervention Type: OTHER; Name: Usual follow up; Assigned to Arm(s): Enhanced education and Enhanced follow up, Usual education with Enhanced follow up | Intervention Type: OTHER; Name: Enhanced follow up; Assigned to Arm(s): Enhanced education and Usual follow up, Usual education and Usual follow up
D: Arm Label: standard support; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: coached group; Type: EXPERIMENTAL; Interventions: Behavioral: telephone-based counselling | Intervention Type: BEHAVIORAL; Name: telephone-based counselling; Assigned to Arm(s): coached group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double Blind, Placebo Controlled Study of the Safety, PK, and PD of Multiple Doses of ISIS 416858 (ISIS-FXI RX), Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
Brief Summary: Evaluation of safety, tolerability, PK and PD of ISIS 416858 in patients with end-stage renal disease (ESRD) receiving chronic hemodialysis.


Options:
A: Arm Label: LMWH arm; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin | Arm Label: UFH arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): LMWH arm | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): UFH arm
B: Arm Label: Citrate dialysate; Type: ACTIVE_COMPARATOR; Interventions: Other: Citrate dialysate | Arm Label: Acetate dialysate; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Citrate dialysate; Assigned to Arm(s): Citrate dialysate
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Vitamin-K antagonists (Phenprocoumon); Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenprocoumon | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Phenprocoumon; Assigned to Arm(s): Vitamin-K antagonists (Phenprocoumon)
D: Arm Label: PK Cohort; Type: EXPERIMENTAL; Interventions: Drug: ISIS 416858 | Arm Label: Cohort A; Type: PLACEBO_COMPARATOR; Interventions: Drug: ISIS 416858, Drug: Placebo | Arm Label: Cohort B; Type: PLACEBO_COMPARATOR; Interventions: Drug: ISIS 416858, Drug: Placebo | Intervention Type: DRUG; Name: ISIS 416858; Assigned to Arm(s): Cohort A, Cohort B, PK Cohort | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort A, Cohort B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness Improving Medication Adherence in Heart Transplant Management
Brief Summary: The purpose of this study is to improve medication adherence, engagement and support to heart transplant patients through implementation of a new clinical care programme conducted by the clinical pharmacy service in cooperation with the heart transplant team and supported by mobile health (mHealth).


Options:
A: Arm Label: SMASK; Type: EXPERIMENTAL; Interventions: Behavioral: SMASK | Arm Label: EnhancedSC; Type: OTHER; Interventions: Behavioral: EnhancedSC | Intervention Type: BEHAVIORAL; Name: SMASK; Assigned to Arm(s): SMASK | Intervention Type: BEHAVIORAL; Name: EnhancedSC; Assigned to Arm(s): EnhancedSC
B: Arm Label: Brand Tacrolimus Only : Prograf; Type: OTHER; Interventions: Drug: Prograf | Arm Label: Generic A Only; Type: OTHER; Interventions: Drug: Tacrolimus | Intervention Type: DRUG; Name: Prograf; Assigned to Arm(s): Brand Tacrolimus Only : Prograf | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Generic A Only
C: Arm Label: Pharmaceutical care programme supported by mHealth; Type: EXPERIMENTAL; Interventions: Other: Multidisciplinary follow-up programme supported by mHealth | Arm Label: Routine healthcare by the transplant team; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multidisciplinary follow-up programme supported by mHealth; Assigned to Arm(s): Pharmaceutical care programme supported by mHealth
D: Arm Label: Tacrolimus + MMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Prednisone, Drug: Mycophenolate mofetil | Arm Label: Envarsus + Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Prednisone, Drug: Everolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Envarsus + Everolimus, Tacrolimus + MMF | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Envarsus + Everolimus, Tacrolimus + MMF | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Tacrolimus + MMF | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Envarsus + Everolimus

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma
Brief Summary: The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined by pulmonary function testing, and effects on asthma control


Options:
A: Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: Symbicort pMDI + budesonide HFA pMDI | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Symbicort pMDI + budesonide HFA pMDI; Assigned to Arm(s): 2
C: Arm Label: QMF149 Twisthaler® 500/400; Type: EXPERIMENTAL; Interventions: Drug: QMF149 Twisthaler® | Arm Label: Mometasone Twisthaler®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone Twisthaler® | Intervention Type: DRUG; Name: QMF149 Twisthaler®; Assigned to Arm(s): QMF149 Twisthaler® 500/400 | Intervention Type: DRUG; Name: Mometasone Twisthaler®; Assigned to Arm(s): Mometasone Twisthaler®
D: Arm Label: QMF149 150/160 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol acetate/Mometasone furoate | Arm Label: QMF149 150/320 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol acetate/Mometasone furoate | Arm Label: MF 400 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone furoate | Arm Label: Salmeterol /fluticasone 50/500 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol xinafoate/fluticasone propionate | Arm Label: MF 800 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone furoate | Intervention Type: DRUG; Name: Indacaterol acetate/Mometasone furoate; Assigned to Arm(s): QMF149 150/160 µg, QMF149 150/320 µg | Intervention Type: DRUG; Name: Mometasone furoate; Assigned to Arm(s): MF 400 µg, MF 800 μg | Intervention Type: DRUG; Name: Salmeterol xinafoate/fluticasone propionate; Assigned to Arm(s): Salmeterol /fluticasone 50/500 μg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Brief Summary: The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic lower extremity distal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult participants with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.


Options:
A: Arm Label: PEG-asparaginase 6 weeks intervals; Type: EXPERIMENTAL; Interventions: Drug: PEG Asparaginase at six weeks interval | Arm Label: PEG-Asparaginase 2 weeks intervals; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEG Asparaginase at two weeks interval | Intervention Type: DRUG; Name: PEG Asparaginase at six weeks interval; Assigned to Arm(s): PEG-asparaginase 6 weeks intervals | Intervention Type: DRUG; Name: PEG Asparaginase at two weeks interval; Assigned to Arm(s): PEG-Asparaginase 2 weeks intervals
B: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Imatinib Mesylate; Assigned to Arm(s): N/A
C: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Brief Summary: The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic lower extremity distal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult participants with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): A, B, C
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin, Drug: chemotherapy with LMWH - enoxaparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: only chemotherapy | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: chemotherapy with LMWH - enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: only chemotherapy; Assigned to Arm(s): B
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D